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ObesityNatriuretic peptides (NPs) are a group of peptide-hormonesmainly secreted from the heart, signaling via c-GMP
coupled receptors. NP are well known for their renal and cardiovascular actions, reducing arterial blood pressure
as well as sodium reabsorption. Novel physiological functions have been discovered in recent years, including
activation of lipolysis, lipid oxidation, and mitochondrial respiration. Together, these responses promote white
adipose tissue browning, increase muscular oxidative capacity, particularly during physical exercise, and protect
against diet-induced obesity and insulin resistance. Exaggerated NP release is a common ﬁnding in congestive
heart failure. In contrast, NP deﬁciency is observed in obesity and in type-2 diabetes, pointing to an involvement
of NP in the pathophysiology of metabolic disease. Based upon these ﬁndings, the NP system holds the potential
to be amenable to therapeutical intervention against pandemic diseases such as obesity, insulin resistance, and
arterial hypertension. Various therapeutic approaches are currently under development. This paper reviews
the current knowledgeon themetabolic effects of theNP systemand discusses potential therapeutic applications.
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Natriuretic peptides (NP) are primarily known for their cardiovascu-
lar and renal actions. Moreover, NP or their fragments are widely
applied as cardiovascular biomarkers in epidemiological studies and in
the clinical routine setting. In particular, NP are important in the diag-
nostic workup of heart failure patients (Maisel et al., 2002). However,
during the last decade, NPs have been shown to exert a variety of
metabolic effects. The purpose of the present review is to give an over-
view of the current knowledge of the metabolic properties of NP and to
summarize therapeutic options that arise from these ﬁndings in the
treatment of the metabolic syndrome and its components.
2. The natriuretic peptide system
2.1. Components and receptor tissue distribution
The endocrine properties of the heart were ﬁrst discovered by
deBold in 1981 when intravenous infusion of a crude atrial myocardial
extract into rats led to a potent natriuretic and diuretic effect (deBold
et al., 1981). Twenty-ﬁve years earlier, granules resembling endocrine
glandshad been discovered in atrialmyocardiumusing electronmicros-
copy (Kisch, 1956). Three years after the ground-breaking discovery by
deBold, the structure of the underlying peptide was identiﬁed and
designated ‘atrial natriuretic peptide’ (ANP) (Kangawaet al., 1984a,
1984b, 1984c). Within the following years, a number of structurally
and functionally related peptides have been identiﬁed to comprise the
NP-hormone family.
To date three members of the NP family, atrial natriuretic peptide
(ANP), brain-type natriuretic peptide (BNP) and C-type natriuretic
peptide (CNP), are considered to play a role in metabolic regulation.
All three natriuretic peptides are secreted as pro-hormones and cleaved
by proteases to reach their ﬁnal, biologically active form. The three
peptides have a 17-amino acid ring structure in common, formed by a
disulﬁde bond between two cysteinyl residues. In humans, the amino
acid sequence of the ring structure is highly preserved within the
three peptides, differing by a few amino acid molecules, only. Both,
ANP and BNP feature peptide speciﬁc amino- and carboxy-terminal ex-
tensions, while CNP lacks the carboxy-terminal appendage (Nishikimi
et al., 2011). ANP is predominantly released from atrial myocardium
where it is produced as a preprohormone and stored as a proANP in in-
tracellular granules (Nakao et al., 1992). The biologically activeαANP is
a 28-amino acid peptide cleaved from proANP by the serine-protease
corin during secretion (Yan et al., 2000). Brain-type natriuretic peptide
was ﬁrst discovered in porcine brain (Sudoh et al., 1988). Today, BNP is
known to be primarily secreted by ventricularmyocardium (Nannipieri
et al., 2002). Similar to ANP, BNP is produced as preproBNP which is
then cleaved to proBNP. Eventually conversion of proBNP to active,
32-amino acid BNP is mediated by the endoprotease furin at the
trans-Golgi network (Nakayama, 1997). Lacking the carboxy-terminal
extension, CNP is the shortest member of the NP family, comprising
22-amino acid residues, only (Nishikimi et al., 2011). It was initially
identiﬁed in porcine brain (Sudoh et al., 1990). CNP is predominantly
present in vascular endothelial cells and in the central nervous system
(Komatsu et al., 1991; Heublein et al., 1992; Stingo et al., 1992; Suga
et al., 1992). Further members of the NP family are urodilatin, which
has been isolated from urine, and Dendroaspis Natriuretic Peptide
(DNP) from the venom of green mamba snakes (Dendroaspis
angusticeps) (Mitsuishi et al., 2008; You & Laychock, 2011). Urodilatin
and DNP have not been well studied upon metabolic effects in humans
and, thus, shall not be further discussed in this review.
Circulating ANP and BNP concentrationsmay differ between healthy
men and women (Vasan et al., 2002; Clerico et al., 2005; Lam et al.,
2011). NPs increase progressively throughout adolescence in girls, and
reach about 2-fold higher levels in normal cycling women compared
to men at the same age (Maffei et al., 2001; Clerico et al., 2002), insome but not all studies. The ANP-precursor gene, NPPR, interacts
with estradiol receptor-α (ER-α) (Mahmoodzadeh et al., 2012). More-
over, estrogen administration in postmenopausal women increases
circulating ANP levels (Maffei et al., 2001). Besides regulating NP
transcription and secretion, estrogens also seem to affect NP-receptor
expression. Estradiol augments Natriuretic peptide receptor A (NPRA)
expression levels, while stabilizing or reducing Natriuretic peptide
receptor C (NPRC) transcription levels, in a tissue and setting dependent
manner in mice (Belo et al., 2008). Possibly, sex dependent NP regula-
tion contributes to the well-known differences in cardiovascular
risk, sympathovagal balance and redistribution of body fat between
women and men, as explained in detail below.
2.2. Natriuretic peptide signaling cascade
NPs exert their effects via NP receptors in a classical endocrineman-
ner. Three subtypes of NP receptors have been described. Natriuretic
peptide receptors A and B (NPRA and NPRB) are guanylyl cyclase (GC)
coupled transmembrane receptors (Waldman et al., 1984; Song et al.,
1988). Ligand binding to NPRA and -B activates the cytosolic GC recep-
tor domain increasing intracellular levels of the second messenger
cGMP. NPRC, the third NP receptor subtype, does not have GC activity,
facilitating NP internalization and degradation, instead (Maack et al.,
1987). Therefore, NPRC is sometimes referred to as clearance receptor.
Additionally, NP are cleared by the neural endopeptidase neprilysin
(NEP) (alternative names: atriopeptidase, common acute lymphocytic
leukemia antigen (CALLA), enkephalinase, neutral endopeptidase
24.11) (Kenny et al., 1993).
The diverse effects of the NP system are determined by NP receptor
distribution and receptor-ligand-afﬁnity and are depicted in part in
Fig. 1. NPRA is regarded as the main effector receptor for ANP and BNP
(Suga et al., 1992). NPRA is abundantly expressed in vascular smooth
muscle and endothelial cells, adipose tissue aswell as in kidney, adrenal
gland, liver and brain and to a lesser extent in the heart (Sarzani et al.,
1996; Bryan et al., 2006). NPRB is structurally similar to NPRA but is
rather activated by CNP in a paracrine fashion (Koller et al., 1991;
Suga, Nakao, Hosoda, et al., 1992). NPRB is expressed by chondrocytes,
where it appears to play a crucial role in enchondral ossiﬁcation during
longbone growth (Yasoda et al., 1998). Disruption of theCNP/NPRB-sig-
naling in mice leads to dwarﬁsm (Chusho et al., 2001; Tsuji & Kunieda,
2005), while CNP overexpression is associated with bone overgrowth
(Kake et al., 2009). Apart from bone, NPRB is highly expressed in
brain, lung, heart, ovary tissue ﬁbroblasts and vascular smooth muscle
cells (Schulz et al., 1989; Nagase et al., 1997). The NP clearance receptor
C is mainly present in adipose tissue and kidney (Nagase et al., 1997).
NPRC is involved in degradation of all three types of natriuretic peptides
with highest afﬁnity to ANP and lowest afﬁnity to BNP (Suga et al.,
1992).
3. Cardiovascular effects of natriuretic peptides
The beneﬁcial effects of NPs on systemic blood pressure and cardiac
remodeling have been investigated thoroughly. The present review fo-
cuses on the metabolic properties of the NP system and the resulting
therapeutic implications. However cardiovascular disease andmetabol-
ic disorders are tightly linked. Therefore the various mechanisms
involved in NP mediated blood pressure regulation will be outlined
brieﬂy.
As ligands for the same receptor, ANP and BNP appear to maintain
similar regulatory actions on blood pressure and cardiac remodeling.
However, ANP and BNP markedly differ in plasma half-life times, with
BNP having an approximately sevenfold longer half-life period
(21 min) than ANP (3 min) (Astrup et al., 1985). The difference in
half-life might be explained by faster clearance of ANP due to a greater
NPRC afﬁnity compared to BNP.
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Fig. 1. Target organs of the natriuretic peptide system. Released by the heart in response to cardiac wall stress, natriuretic peptides act on vascular system, kidneys and brain. In order to
reduce blood pressure and the resulting cardiac burden, NPs reduce vascular tone, enhance renal sodium and water excretion, inhibit the renin–angiotensin–aldosterone system (RAAS)
and attenuate central nervous sympathetic nervous system activity. Moreover, natriuretic peptides exert metabolic effects in a numerous organs. In human adipose tissue, NPs enhance
lipolysis as well as the secretion of the insulin sensitizing adipokine adiponectin, while leptin release is suppressed. At the same time, natriuretic peptides enhance mitochondrial biogen-
esis and oxidative capacity in skeletal muscle and adipose tissue. Inwhite adipose tissue (WAT)mitochondrial biogenesis leads to browning of adipocytes, enhancing energy expenditure
and heat production. Natriuretic peptidesmight also improve pancreatic insulin secretion. All thesemechanismsmight play together to control whole body energy homeostasis. ANP atrial
natriuretic peptide; BNP brain natriuretic peptide; HSL hormone sensitive lipase.
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dent manner (Protter et al., 1996; van der Zander et al., 1999). Mice
with endothelium restricted NPRA deletion feature arterial hyperten-
sion with a paradoxically normal vasodilatory response to ANP
(Sabrane et al., 2005). Endothelial NPRA appears to affect endothelial
permeability, thus, regulating ﬂuid shifts between the interstitial and
intravascular compartment (Sabrane et al., 2005). Cardiomyocyte
restricted NPRA disruption in mice is associated with ﬁve times higher
ANP concentrations compared towild type and comes alongwithmark-
edly reduced blood pressure levels (Holtwick et al., 2003). Heart speciﬁc
NPRA disruptionwas also associatedwith pressure independent cardiac
hypertrophy, conﬁrming anti-cardiohypertrophic properties of NP
(Tamura et al., 2000; Kishimoto et al., 2001; Holtwick et al., 2003).
Moreover, NPs acutely reduce plasma volume in part by enhancing na-
triuresis (Yoshimura et al., 1991). ANP augments glomerular ﬁltration
rate (GFR) through escalation of glomerular capillary pressure and
expansion of mesangial cell ﬁltration surface (Fried et al., 1986;
Marin-Grez et al., 1986). Additionally, NPs inhibit water and sodium
re-uptake in the proximal tubule and the collecting duct (Sonnenberg
et al., 1986; Harris et al., 1987).
In addition to the direct cardiovascular and renal effects, NPs inhibit
the renin–angiotensin–aldosterone-system (RAAS) by suppressing
renal renin release (Burnett et al., 1984; Johnson et al., 1988; Shi et al.,
2001). Besides peripheral regulatory effects on blood pressure, NPs
modulate sympathetic activity in the central nervous system (Floras,
1990; Schroeder et al., 2006). CNP does not seem to have a signiﬁcant
effect on renal sodium andwater excretion (Pham et al., 1997). Howev-
er, CNP is considered to cause vascular smooth muscle relaxation and
inhibition of smooth muscle proliferation in a paracrine manner(Furuya et al., 1990; Furuya et al., 1991). Yet, CNP−/−mice do not de-
velop severe arterial hypertension, indicating that CNP might not play
an important role in blood pressure and ﬂuid homeostasis (reviewed
by Schulz) (Schulz, 2005).
4. Metabolic effects of natriuretic peptides
4.1. Natriuretic peptide activated lipolysis
The regulation of lipolysis in adipose tissue has been thoroughly
investigated (Lafontan & Langin, 2009; Ahmadian et al., 2010; Zechner
et al., 2012). For many years, catecholamines were considered to be the
major physiological lipolytic agent. Catecholamines induce lipolysis via
stimulation of adipocyte adrenergic β-receptors and subsequent cAMP
dependent activation of hormone sensitive lipase (HSL) (Stralfors &
Belfrage, 1983; Stralfors et al., 1984; Egan et al., 1992). The exact mech-
anism of adipose triglyceride lipase (ATGL) activation in the process,
hydrolyzing the ﬁrst fatty acid from triacylglycerols, is still amatter of re-
search (Zechner et al., 2012). Insulin is themajor endogenous inhibitor of
catecholamine dependent lipolysis (Coppack et al., 1989; Jensen et al.,
1989). Insulin abolishes adipose tissue lipolysis via phosphodiesterase
3B (PDE3B) activation which subsequently leads to cAMP degradation
and deactivation of PKA (Choi et al., 2006).
A decade ago, NP entered the ‘lipolytic arena’. Potent lipolytic proper-
ties of natriuretic peptideswere ﬁrst described by Sengenès et al. (2000).
The authors observed that all three subtypes of the NP family promote li-
polysis in human adipose tissue, with ANP being themost potent activa-
tor of lipolysis, followed by BNP and CNP in descending order (pEC50:
ANP 9.82 ± 0.20; BNP 8.33 ± 0.08; CNP 7.75 ± 0.58 [−log EC50]).
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NPRC expression in other mammalian adipocytes (Sengenès et al.,
2002). Indeed; NPRC deletion fully restored the lipolytic properties of
natriuretic peptides in mice (Bordicchia et al., 2012).
Unlike catecholamines, NPs resort to a cGMP dependent, protein
kinase G activating, pathway. NP driven activation of protein kinase G
(GK-I) promotes perilipin A andhormone sensitive lipase (HSL)mediat-
ed triglyceride degradation (Sengenès et al., 2000, 2003; Birkenfeld
et al., 2005). Relying on different pathways, the lipolytic actions of
NP's and catecholamines in humans seem to be completely indepen-
dent (Galitzky et al., 2001; Birkenfeld et al., 2006). Simultaneous stimu-
lationwith ANP and β-adrenergic agonists such as isoproterenol results
in additive potentiation of the lipolytic effects in human adipocytes
(Moro et al., 2004).
Remarkably, insulin does not seem to have a direct antilipolytic
effect on the cGMP/GK-I dependent lipolytic pathway (Moro et al.,
2004; Moro et al., 2005).
However, insulin might attenuate NP mediated lipolysis indirectly
by reducing circulating NP levels. Furthermore, insulin may reduce
NPRA expression while reciprocally enhancing NPRC expression in
white adipose tissue in rodents and humans (Nakatsuji et al., 2010;
Pivovarova et al., 2012). In fact, short-term insulin infusions reduced cir-
culating NT-pro-BNP and MR-pro-ANP levels in humans (Halbirk et al.,
2010; Pivovarova et al., 2012) and interventions increasing insulin sen-
sitivity increase MR-pro-ANP levels (Rudovich et al., 2012).
Besides direct activation of lipolysis, other relevant effects on
adipose tissue have been described. Sarzani et al. hypothesized that
ANP may attenuate human adipocyte growth (Sarzani et al., 2007).
However, this issue needs further study to fully delineate the effect of
NPs in adipogenesis. Moreover, Moro and colleagues showed that ANP
inhibits the release of pro-inﬂammatory cytokines and chemokines
from human adipocytes and adipose tissue macrophages (Moro et al.,
2007). The mechanism could be beneﬁcial because chronic, low grade
inﬂammation contributes to obesity-associated insulin resistance and
cardiovascular disease.
4.2. Natriuretic peptides enhance lipid
oxidation and mitochondrial respiration
NP induced lipolysis acutely increases free fatty acid (FFA) availabil-
ity in human subjects (Galitzky et al., 2001; Birkenfeld et al., 2005, 2006,
2011a). Apparently, these fatty acids serve as substrates for oxidative
tissues such as skeletal muscle, liver, and ‘beige’ and brown adipose tis-
sue. Moreover, studies in humans and mice indicate that NPs enhance
lipid oxidation in adipose tissue, skeletal muscle and liver, allowing
these tissues to fuel fatty acids into the β-oxidation pathway at an
increased rate.
We observed that short term intravenous administration of ANP
acutely increases lipid oxidation (Birkenfeld et al., 2005, 2012) and
postprandial energy expenditure in healthy men (Birkenfeld et al.,
2008). In the latter study, circulating beta-hydroxybutyrate increased
markedly, indicating that hepatic lipid oxidation at least in part contrib-
uted to the acute response. Molecular mechanisms might include dis-
tinct pathways. First, FFAs from acute β-adrenergic receptor mediated
lipolysis seem to increase mitochondrial respiration and lipid oxidation
by an effect on uncoupling protein 3 (UCP3) activity in skeletal muscle
(Hoeks et al., 2003). The mechanism might also be applicable to the
NP system. Second, apart from acute lipid oxidation enhancement
(Birkenfeld et al., 2008), ANP and BNP induce skeletalmusclemitochon-
drial biogenesis, respiration and lipid oxidation in human cells and in
rodents, in vitro and in vivo (Miyashita et al., 2009). Chronic overex-
pression of BNP and GK-I each led to increased muscle mitochondrial
content, oxidative capacity and lipid oxidation in mice. Enhanced
oxidative metabolism was associated with protection from high
fat diet (HFD) induced obesity and insulin resistance. Heterozygous
NPRA knockout was associated with increased susceptibility to weightgain and insulin resistance in mice (Miyashita et al., 2009). The mecha-
nism driving improvements in mitochondrial biogenesis and lipid
oxidation in skeletal muscle included the induction of peroxisome
proliferator–activated receptor γ coactivator (PGC)-1α and peroxisome
proliferator–activated receptor (PPAR)-δ genes, two master regulators
of mitochondrial biogenesis in skeletal muscle (Miyashita et al., 2009).
In humanmyotubes, we showed that ANP and BNP, as well as cGMP
analogs, induced PGC-1α, mitochondrial respiration and lipid oxidation
(Engeli, et al., 2012). Furthermore, NPRA expression was associated
with PGC-1α expression in skeletalmuscle of healthy physically trained
human subjects. Supporting evidence comes from cell culture studies
showing that cGMP restores glucose and insulin inducedmitochondrial
dysfunction in cultured C2C12 myotubes (Mitsuishi et al., 2008). In the
same vein, nitric oxide signals via cGMP to mediate the induction of
PGC-1α and mitochondrial biogenesis in various murine tissues
(Nisoli et al., 2003). Activation of PGC-1α enhances activity of PPARs,
nuclear receptors with transcriptional activity on genes involved in
lipid oxidation and mitochondrial function (Puigserver et al., 1999;
Schupp& Lazar, 2010).Moreover,mitochondrial biogenesis requires ex-
pression of nuclear encoded mitochondrial genes that are under the
control of several transcription factors including the nuclear respiratory
factors (NRFs) (Kelly & Scarpulla, 2004). PGC-1α is a key regulator of
NRF-1 and 2, which control a network that includes respiratory chain
subunits and parts of mitochondrial DNA transcription machinery
(Kelly & Scarpulla, 2004). Importantly, PGC-1α also induces mitochon-
drial UCP1 in adipose tissue and UCP3 in skeletal muscle through inter-
action with PPARγ (Puigserver et al., 1999). Intriguingly, ANP and BNP
not only induced PGC-1α expression in human myotubes, but also an
array of downstream target genes, such as NRF1, UCP-3 and complexes
I and IV of the respiratory chain (Engeli, et al., 2012). Together, these
data suggest, that NPs induced lipid oxidation and mitochondrial respi-
ration in skeletal muscle is induced through a cGMP driven, GK-I medi-
ated effect on PGC-1α, inducing transcription of downstream targets,
such as NRF-1 and UCP3, probably via PPARα and/or PPARδ. The signal-
ing cascade is depicted in Fig. 2.
In white and ‘beige’ (brite) adipose tissue, NPs mediate similar ef-
fects (see below). In these tissues, activation of p38 mitogen activated
protein kinase (p38 MAPK) by GK-I might play a role (Bordicchia
et al., 2012). Moreover, Souza et al. showed that ANP inducesmitochon-
drial biogenesis and up-regulates expression of mitochondrial genes in-
volved in fatty acid transport and oxidation in human adipocytes via
NPRA by GK-I dependent activation of AMP-activated protein kinase
(AMPK) (Souza et al., 2011), a master energy sensor acting as a nod in
intracellular energymetabolism. AMPK induces PGC-1α via direct phos-
phorylation to increase transcriptional activity of PGC-1α (Jäger et al.,
2007). AMPK is generally induced via an increased ratio of AMP to
ATP, or calcium via distinct kinases. More studies are clearly needed to
put the pieces together. Identiﬁcation of the initial molecular mecha-
nisms involved in NP enhanced mitochondrial respiration may lead to
novel targets for the treatment of metabolic disease.
4.3. Natriuretic peptides and browning of white adipose tissue
Recently, the signiﬁcance of mitochondrial metabolism in adipose
tissue has been revisited by showing that brown adipose tissue mass
and function is more relevant in humans than previously appreciated.
Moreover, adipocytes in human white adipose tissues can switch
from white to brown and vice versa (‘brite’ or ‘beige’ adipose tissue)
(Cypess et al., 2009). Fat is mainly stored in white adipose tissue
(WAT). Brown adipose tissue (BAT) is another fat reservoir, which in
contrast to WAT is able to generate heat and maintain body tempera-
ture. Brown adipocytes are located in the BAT and smaller populations
were identiﬁed within WAT. BAT evolved in mammals to dissipate
large amounts of biochemical energy in form of heat for defending the
cold (Smith & Roberts, 1964). Upon cold exposure, BAT is activated by
central nervous mechanisms through the sympathetic nervous system.
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16 N. Schlueter et al. / Pharmacology & Therapeutics 144 (2014) 12–27The thermogenic response in brown adipocytes ismediated by uniquely
enriched mitochondria expressing UCP1 in the inner membrane
(Ricquier & Kader, 1976; Heaton et al., 1978; Lin & Klingenberg, 1980;
Ricquier et al., 1983). UCP1 allows brown adipocytes to dissipate the
electrochemical gradient that is normally used to drive ATP synthesis
(Klingenberg, 1999). However, the thermogenic response cannot solely
be explained by UCP1, since the expression of several genes involved in
energy metabolism is increased in experimental animals to a cold envi-
ronment (Stralfors & Belfrage, 1983; Egan et al., 1992). Bordicchia et al.
recently demonstrated the importance of NPRA and NPRB in BAT
(Bordicchia et al., 2012).
Adrenergic stimulation increases energy dissipation in BAT, proba-
bly reducing body weight in obese individuals (Astrup et al., 1985;
Finer et al., 2000). However, adrenergic compounds have the potential
to increase stroke and myocardial infarction risk, likely through inﬂu-
ences on heart rate and blood pressure (Haller & Benowitz, 2000;
Torp-Pedersen et al., 2007). Catecholamines raise intracellular cAMP, di-
rectly activating PKA (cAMP dependent protein kinase), which phos-
phorylates HSL and kinases of the p38 MAPK pathway (Cao et al.,
2001, 2004). p38 MAPK inhibition attenuates adrenergically mediated
UCP1 expression (Cao et al., 2004). Bordicchia et al. demonstrated that
mice, lacking the negative regulator of NP activity NPRC−/−, have re-
duced WAT and lipid accumulation in BAT with enhanced expression
of thermogenic genes in both tissues (Bordicchia et al., 2012). Treat-
ment of a humanderived adipocyte cell linewithANP results in GK-I de-
pendent induction of thermogenic and mitochondrial genes, leading to
an uncoupling of respiration (Bordicchia et al., 2012). NPs elicited the
response by increasing p38 MAPK signaling and phosphorylation of
ATF2, directly increasing UCP1 transcription in brown adipocytes
(Bordicchia et al., 2012). BNP treatment in mice enhanced energyexpenditure and increased thermogenic protein levels in BAT and
WAT (Bordicchia et al., 2012).With cold exposure, circulating NP levels
and BAT NPRA expression increases while NPRC expression decreases
(Bordicchia et al., 2012). Similarly, forced GK-I expression in primary
adipocytes induces a strong increase in UCP-1 and activates a brown-
like thermogenic program. Treatment of micewith the phosphodiester-
ase 5 inhibitor sildenaﬁl elicited a similar response (Pfeifer et al., 2013).
Together, these studies show that similarly to skeletal muscle, the NP
system induces a thermogenic program in adipose tissue. A schematic
representation is given in Fig. 3. By these means, the NP axis seems to
be involved in the physiological BAT adaptation to changes in environ-
mental temperature (Carey & Kingwell, 2013; Schulz & Tseng, 2013).
4.4. Natriuretic peptide interactions with adipokines
Besides a direct activating effect on lipolysis and lipid oxidation, NPs
also seem to have a regulatory sway on certain adipokines involved in
energy metabolism. ANP acutely increases systemic levels of total and
high molecular weight (HMW) adiponectin, an insulin sensitizing
adipokine, in human subjects (Tanaka et al., 2008; Birkenfeld et al.,
2012). These ﬁndings are in accordancewith a number of observational
studies showing positive associations between circulating NP and
adiponectin levels, as for example in heart failure patients (Kistorp
et al., 2005; Hara et al., 2011; Azizi Ghanbari et al., 2013). Leptin may
be another NP regulated adipokine. ANP reduces leptin release from
human adipocytes (Fain et al., 2003). These ﬁndings are supported
in vivo by a recent clinical investigation.Melenovsky and coworkers ob-
served a signiﬁcant inverse relationship between systemic BNP levels
and plasma concentrations of the anorexigenic adipokine leptin in
heart failure patients (Melenovsky et al., 2013). To date, themechanism
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NPRA
cGMP
GC-A
NPRC
GK-I
(PKG)
X
Triglycerides
HSL
Perilipin
β-adrenoreceptor
GTP
cAMP
PKA
ATP
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Insulin-
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Catecholamines
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AKT
Adipocyte
AC
p38-
MAPK
Mitochondrial biogenesis 
energy expenditure
heat production
„WAT browning“
AMPK
Energy uptake
adiponectin release
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Fig. 3. NP related effects in human adipocytes. ANP and BNP induce a cGMP dependent pathway via stimulation of natriuretic peptide receptor A. Increased intracellular cGMP levels
activate cGMP dependent protein kinase G which induces lipolysis through phosphorylation of hormone sensitive lipase. At the same time, enhances mitochondrial biogenesis via
activation of AMPK and p38-MAPK, leading to browning of white adipose tissue. Unlike catecholamine induced lipolysis, the cGMP dependent lipolytic pathway is independent of the
antilipolytic effects of insulin. ANP atrial natriuretic peptide; BNP brain type natriuretic peptide; NPRA natriuretic peptide receptor A; NPRC natriuretic peptide receptor C; GCA guanylyl
cyclase A; GTP guanosine triphosphate; cGMP cyclic guanosine monophosphate; PKG protein kinase G; ATP adenosine triphosphate; AC adenylyl cyclase; cAMP cyclic adenosine
monophosphate; PKA protein kinase A; HSL hormone sensitive lipase; ATGL adipocyte triglyceride lipase; AMPK AMP-activated protein kinase; p38-MAPK mitogen-activated protein
kinase; AKT protein kinase B.
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stood. In conditions with decreased NP levels, such as in obesity, the
mechanism might contribute to metabolic disease (Wang, 2012).
4.5. Natriuretic Peptides, insulin secretion and glucose homeostasis
A number of studies suggest that NP directly and indirectly affect
glucose metabolism. We and others observed increased insulin levels
during ANP infusion in human subjects (Uehlinger et al., 1986;
Birkenfeld et al., 2005, 2008). The effect might be explained by a direct
modulating effect on β-cell function or, less likely in the acute setting,
on β-cell mass (Ropero et al., 2010). ANP directly enhanced glucose-
stimulated insulin secretion in cultured islets. In addition, ANP induced
β-cell growth in isolated rat pancreatic islets (You & Laychock, 2009),
whereas signiﬁcantly smaller islets with reduced β-cell mass are
found in knockout mice. Thus, ANP might increase glucose uptake via
stimulation of pancreatic insulin release.
Interestingly, ANP infusion in ten fasting, healthy youngmen slightly
increased circulating glucose levels (Birkenfeld et al., 2005). This effect
might be explained by the acute effect of ANP on lipid mobilization,
acutely increasing the ﬂux of fatty acids tometabolic, insulin responsive
organs and thereby inducing insulin resistance (Nowotny et al., 2013;
Birkenfeld & Shulman, 2014), an effect that can be outbalanced in thelong-termby increased usage of these fatty acids inβ-oxidation. The no-
tion that lipidmobilization enhances the distribution of fatty acids to ec-
topic organs inducing insulin resistance, is supported by the fact that
short-term infusion of BNP, in a manner not increasing fatty acid levels,
lowered circulating glucose concentrations slightly during the initial
phase of an intravenous glucose tolerance test, together with reduced
insulin secretion. In this case, the effect could be mediated by the
increase in peripheral vasodilation (Heinisch et al., 2012) and through
improved glucose transport across the capillary wall into the interstitial
space (Jensen et al., 1998). Together, these studies suggest that NP
might enhance insulin-stimulated glucose disposition. Whether or not
NPs directly affect insulin signaling deserves to be studied in more
detail.
Hepatic and skeletal muscle lipid content is strongly associated with
insulin resistance (Samuel & Shulman, 2012; Birkenfeld & Shulman,
2014). In liver and skeletal muscle, insulin resistance develops when
there is an imbalance between supply and utilization of intracellular
lipid leading to net accumulation of bioactive lipid species, such as
intracellular diacylglycerol (DAG hypothesis) (Birkenfeld & Shulman,
2014). In obesity and metabolic syndrome, this lipid accumulation is
primarily achieved by excessive caloric intake exceeding the capacity
of hepatocytes and myocytes to metabolize or export fatty acids while
reﬁning or uncoupling mitochondrial respiration and enhancing lipid
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2010; Thielecke et al., 2010; Birkenfeld et al., 2011b, 2011c;
Kumashiro et al., 2013; Perry et al., 2013; Neuschafer-Rube et al., 2014).
NPs could ameliorate lipid-induced insulin resistance through im-
provements in hepatic (Birkenfeld et al., 2008) and muscular (Engeli
et al., 2012) lipid oxidation. In line with the notion, NPs preserve mito-
chondrial function and insulin sensitivity in high fat feeding in mice
(Miyashita et al., 2009). Cross sectional studies support the hypothesis
that NPs protect from the development of T2D and are explained in de-
tail below. Investigation of the effect of BNP on insulin sensitivity in in-
dividuals with impaired glucose tolerance or frank diabetes would be of
interest now that data on healthy participants are available.
4.6. Natriuretic peptides in food intake and satiety
As mentioned above, NPRB, the CNP receptor, is predominantly
found in the brain. Therefore it has been suggested that CNP might
play a role in the central regulation of energy metabolism and food
intake. The hypothesis is supported by a recent study testing intra-
cerebroventricular application of different CNP variants in mice. The in-
tervention substantially decreased food intake after a 48 h-fast and
nocturnal food intake, whereas intraperitoneal CNP injection did not
alter feeding behavior. Anorexigenic effects of CNP are evoked by
melanocortin system activation as well as suppression of orexigenic
mediators such as ghrelin and neuropeptide Y (NPY) (Yamada-Goto
et al., 2013). In human subjects, short-term BNP infusion suppress hun-
ger, perhaps by decreasing total and acetylated ghrelin concentrations
(Vila et al., 2012). However, regulation of food intake is complex and
NP inﬂuence on hunger and satiety is a still emerging research ﬁeld.
To date, it is unknownwhether BNP's anorexigenic effects are mediated
by stimulation of hypothalamic AMP-activated protein kinase (AMPK)
through ghrelin, or another regulator of hypothalamic AMPK activity.Table 1
Metabolic phenotypes.
Genetic variation NP related effect Phenoty
NPRC−/−mice ↑ ANP ↑ bone m
↑ long bo
↓ blood p
↑ urine e
↓WATm
↑ energy
BNP-Tg mice ↑ BNP ↓ body w
↓ viscera
↓ diet-in
↑ glucose
↑muscle
↑ lipid ox
cGK-Tg mice ↑ cGMP ↓ body w
↓ viscera
↓ diet-in
↑ glucose
↑muscle
↑ lipid ox
GC-A+/−mice ↓ cGMP-signaling ↑ body w
↑ fat mas
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BNP promoter
T-381C polymorphism
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↑ BNP ↓ blood g
↓ T2DM-
rs5068
(humans)
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= BNP
↓ blood p
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NPRC polymorphism C(−55)A ↑ ANP ↓ blood p
↓ BMI an
Neprilysin−/−mice ↑ body w
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Correlations between natriuretic peptide system related genetic and cardiometabolic phenoty
white adipose tissue; T2DM type 2 diabetes mellitus; HDL high-density lipoprotein; VLDL veryInsulin, glucose and certain fatty acids might be involved in the regula-
tion of satiety through BNP (Jens Jordan& Birkenfeld, 2012). Additional-
ly, high BNP levels are associated with suppressed levels of the
anorexigenic adipokine leptin in heart failure patients, suggesting a reg-
ulatory effect of the NP system on leptin release. An increase in food in-
take may ensue (Melenovsky et al., 2013). Clearly, the effect of NP on
leptin release warrants careful clinical studies to better understand the
importance of NP on adipokines such as leptin.
A summary of the metabolic actions and phenotypes of NP animal
models and human polymorphisms is given in Table 1.
5. Natriuretic peptides in human cardiometabolic disease
5.1. Natriuretic peptides in obesity
During the last years, numerous studies demonstrated an inverse
relationship between circulating NP levels and bodyweight (Wang
et al., 2004; Das et al., 2005; Olsen et al., 2005; Sugisawa et al., 2010;
Khan et al., 2011; Cannone et al., 2013). This correlation can also be
observed in chronic heart failure patients, despite increased NP levels,
due to cardiac wall stress (Stavrakis et al., 2013).
Increased NP levels due to a genetic C(−55)A polymorphism of the
NPRC are associated with lower prevalence of obesity and abdominal
adiposity compared to individuals with intact NPRC (Sarzani et al.,
2004). Another genetic polymorphism, in the ANP-promoter region, is
associated with higher ANP levels and a favorable cardiometabolic
phenotype including lower BMI and blood pressure as well as lower
prevalence of obesity and metabolic syndrome (Newton-Cheh et al.,
2009; Cannone et al., 2011; Arora et al., 2013; Cannone et al., 2013).
However, some studies show discordant results, indicating that
there is no or even a positive correlation between BMI and systemic
NP concentrations (Grandi et al., 2004; Abdulle et al., 2007). Elevatedpe Publication
etabolism, delayed enchondral ossiﬁcation
ne growth
ressure
xcretion
ass
expenditure
Jaubert et al., 1999
Matsukawa et al., 1999
Bordicchia et al., 2012
eight
l and subcutaneous fat mass
duced ectopic fat accumulation
tolerance
mitochondrial content
idation rate
Miyashita et al., 2009
eight
l and subcutaneous fat mass
duced ectopic fat accumulation
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Miyashita et al., 2009
eight
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Miyashita et al., 2009
lucose levels
risk
Meirhaeghe et al., 2007
Choquet et al., 2009
ressure
d prevalence of obesity
Newton-Cheh et al., 2009
Arora et al., 2013
Cannone et al., 2011, 2013
ressure
d prevalence of obesity
Sarzani et al., 1999, 2004
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resistance
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Becker et al., 2010
pes Tg transgenic; cGK cGMP dependent protein kinase G; GC-A guanylyl-cyclase; WAT
low- density lipoprotein ↑ increase; ↓ decrease; = no change.
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have been reported in morbidly obese patients (BMI N 40 kg/m2). How-
ever, the authors relate their ﬁndings to the enormous cardiac burden
secondary to morbid obesity (Hermann-Arnhof et al., 2005). Yet, it is
widely agreed that obesity is a state of a NP deﬁciency. Differences in
sample handling and analytical techniques could contribute to the vari-
ability (Buckley et al., 1999; Nowatzke& Cole, 2003; Belenky et al., 2004).
In lean, healthy subjects cardiac NP deﬁciency release is acutely en-
hanced by physical exercise (Moro et al., 2004a; Scharhag et al., 2005;
Frassl et al., 2008; Knebel et al., 2009; Tian et al., 2012; Baker et al.,
2013). In marathon runners NT-proBNP increased directly after the
run while BNP showed a delayed reaction (Frassl et al., 2008). Interest-
ingly both hormones show a sustained increase during the ﬁrst 24 h after
prolonged running with a delayed return to basal levels more than 24 h
after the run (Frassl et al., 2008; Tian et al., 2012).
In contrast to lean subjects, circulating NP levels are suppressed
and acute NP responses are blunted in obese individuals (Koppo
et al., 2010) but can be restored by long-term physical training (C.
Moro et al., 2005; Chen-Tournoux et al., 2010; Changchien et al.,
2011; Abrahamsson et al., 2013; Martin et al., 2013). Investigation
of a total of 7770 subjects who participated in the Framingham
Heart Study and the Malmö Diabetes and Cancer Study revealed
that obesity and insulin resistance are associated with markedly
reduced plasma NP levels (Khan et al., 2011). Clinically relevant
hypercortisolism comes along with central adiposity and the full
range of metabolic syndrome symptoms. Despite the metabolic
phenotype, NP levels seem to be increased in subjects with
hypercortisolism (Yamaji et al., 1988; Tabarin et al., 1990). Elevated
NP levels might be attributed to cardiovascular diseases, a major de-
terminant of mortality in hypercortisolism (Mancini et al., 2004; Toja
et al., 2012; Shibusawa et al., 2013). Interestingly, NP response ap-
pears to be blunted in hypercortisolism, despite elevated NP levels
(Sala et al., 2001). However, the role of NP in clinically relevant
hypercortisolism is still a controversial issue and alterations in NPNP plasm
Obesity
Ectopic lipid accumulation
Adipose tissue
NPRC-expression
Fig. 4. Obesity is associated with impaired NP release and increased expression of the NP degra
contributes to insulin resistance and mitochondrial dysfunction which in turn lead to hypergly
resistance and natriuretic peptide deﬁciency emerge to a viscous cycle.receptor distribution and signaling due to hypercortisolism deserve
further investigation.
So far, several potential reasons for the relative NP deﬁciency in
humanmetabolic disease have been considered. Increased NP degrada-
tion could be one possible cause of decreased NP plasma levels in obese
individuals. As mentioned before, natriuretic peptides are cleared by
neutral endopeptidase neprilysin and NPRC (Maack et al., 1987;
Kenny et al., 1993). NPRA and NPRC have been identiﬁed in human
adipose tissue in abundance, implying that adipose tissue is not just a
target organ for NP but alsomaintains a regulatory inﬂuence on circulat-
ing NP levels (Sarzani et al., 1996; Nakatsuji et al., 2010; Pivovarova
et al., 2012). NPRC is increased in adipose tissue of obese hypertensive
patients compared to non-obese and normotensive individuals (Dessi-
Fulgheri et al., 1997). Moreover; hyperinsulinemia induces NPRC ex-
pression in human adipocytes (Nakatsuji et al., 2010) and monocytes
(Pivovarova et al., 2012). Additionally, neprilysin, the NP degrading en-
dopeptidase, is expressed in human adipose tissue and at increased
levels in obesity (Standeven et al., 2011). Taken together these ﬁndings
militate for an accelerated NP clearance due to a shift in the NPRA/NPRC
ratio towards NPRC and increased neprilysin levels in humanmetabolic
disease, emerging to a vicious cycle of NP suppression, obesity and
insulin resistance (Fig. 4).
In linewith the notion, caloric restriction andweight loss can restore
BNP levels in humans (Chainani-Wu et al., 2010) and NP signaling
in rodents by decreasing adipose tissue NPRC expression (Sarzani
et al., 1995). This effect might in part be attributed to reduced
hyperinsulinemia (Chainani-Wu et al., 2010).
Apart from their general association with lower body fat mass, NPs
may favorably affect adipose tissue distribution. Increased NP levels
are associated with reductions in visceral adipose tissue (VAT) and in
ectopic, intra-organ fat deposition such as intrahepatic lipid accumula-
tion (Sarzani et al., 2004; Cheng et al., 2011; Neeland et al., 2013). One
possible explanation is increased susceptibility to NPmediated lipolysis
in VAT due to increased NP receptor expression in VAT compared toa levels
Insulin-resistance
Mitochondrial function
Hyperinsulinemia
Hyperglycemia
ding receptor NPRC, leading to a signiﬁcant reduction of systemic NP levels. NP deﬁciency
cemia and increased insulin levels resulting in further weight gain. Thus, obesity, insulin
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possible explanation is that SAT generally exhibits less lipolytic activity
than VAT (Arner, 1995).
There are also indications of an impaired cardiac NP release in met-
abolic diseases. In obese individuals, reduced saline load-induced NP re-
sponses were observed as early as 20 years ago (Licata et al., 1994).
More recently, a number of studies demonstrated that circulating levels
of NT-proANP andNT-proBNP are reduced in obesity, too. Asmentioned
above, NT-proANP and NT-proBNP are side-products of NP release.
These peptides are cleaved of the amino-terminus of the inactive
prohormones to produce biologically active ANP and BNP (Yan et al.,
2000). The aminoterminal cleavage products of ANP and BNP are struc-
turally distinct from the biologically active peptidesmakingNPRCmedi-
ated degradation unlikely (Minami et al., 2004; Das et al., 2005).Mizuno
et al. recently observed that differences between BNP levels measured
in the aortic root and BNP levels in the coronary sinus are negatively
correlated with BMI, supporting the hypothesis of an impaired myocar-
dial NP release in obese individuals (Mizuno et al., 2013). Others
observed correlations between NP plasma levels and lean body mass
rather than fat mass (Das et al., 2005; Asferg et al., 2013a, 2013b).
Interestingly; lower NP levels were strongly related to high glucose
and insulin levels independent of body composition and adipose tissue
distribution (Asferg et al., 2013a, 2013b).
5.2. Natriuretic peptides in insulin resistance and diabetes
A potential connection between plasma glucose and insulin levels
and the natriuretic peptide system has been observed in several studies.
Acute hyperglycemia induces a rapid rise of ANP levels in response to
hyperglycemia induced sodium and ﬂuid retention (Clark et al., 1993;
Böhlen et al., 1994; McKenna et al., 2000). On the other hand, low BNP
levels are associated with insulin resistance and type 2 diabetes (T2D)
(Kroon et al., 2012). This correlation can be partially explained by the
association of T2D and obesity. However; statistical correction for BMI
does not abolish the correlation between NP-levels and diabetes onset.
Data from the Women's Health Study revealed that individuals with
NT-proBNP levels near the upper limit of normal have signiﬁcantly
lower incidence of diabetes (Everett et al., 2013).
Large cross-sectional studies conﬁrm the relationship between low
NP concentrations and high glucose and insulin levels, as well as high
plasma cholesterol and triglyceride concentrations (Olsen et al., 2005;
Wang et al., 2007). Data from a total of 7770 participants in the
Framingham Heart Study and the Malmö Diet and Cancer Study
revealed that lower NP levels are associated with higher susceptibility
to insulin resistance in both lean and obese individuals (Khan et al.,
2011). Moreover, in the cohort of the longitudinal Malmö Diet and Can-
cer Study low NP concentrations were clearly predictive of new-onset
diabetes aswell as blood glucose level progression over the study period
(Magnusson et al., 2012). Correspondingly, increased NP levels seem to
be protective against insulin resistance (Neeland et al., 2013) and T2D
(Pﬁster et al., 2011; Cannone et al., 2013; Everett et al., 2013). Along
these lines, Heinisch et al. observed that BNP infusion during intrave-
nous glucose tolerance testing lowers blood glucose concentrations
transiently by increasing glucose distribution volume in healthy men
(Heinisch et al., 2012). These ﬁndings suggest that NPs might be
protective against T2D due to a direct, insulin-independent anti-
hyperglycemic effect, and by increasing lipid oxidation rates and
pertaining mitochondrial function as outlined before. Vice versa, NP
deﬁciency contributes and aggravates at least in part metabolic disease,
such as insulin resistance and diabetes on the long run.
Another interesting link has recently been discovered between
glucagon-like peptide-1 receptor (GLP-1R) agonists and natriuretic
peptide release. GLP-1R agonists are a group of antidiabetic drugs that
enhance insulin secretion and suppress glucagon release (Drucker &
Nauck, 2006). In addition, GLP-1 receptor agonists promote satiety
and weight loss while decreasing blood pressure (Ussher & Drucker,2012). Heart rate tends to increase with GLP-1R agonist treatment.
The mechanism of the cardiovascular side effects is still incompletely
understood. However, Kim et al. recently demonstrated that the GLP-
1R agonist liraglutide induces cardiac ANP release in mice, leading to
enhanced natriuresis and vasodilatation (Kim et al., 2013). An increase
in heart rate could, hence, be a compensatory response.
5.3. Natriuretic peptides in cardiovascular diseases
Another facet of metabolic diseases is the link between obesity and
arterial hypertension. Obese individuals have a two- to threefold higher
prevalence of arterial hypertension compared to lean subjects (Stamler
et al., 1978). Althoughmanyaspects of obesity related arterial hyperten-
sion have been intensively studied during the last years, not all mecha-
nisms are well understood (Aneja et al., 2004; Jordan & Engeli, 2012). In
lean healthy individuals, administration of sodium load or vasopressors
induces myocardial NP release and consequently enhances natriuresis
(Uehlinger et al., 1987; Clinkingbeard et al., 1990; Bruun et al., 2000;
Park et al., 2013). The response is impaired in obese individuals
(Asferg et al., 2013a, 2013b). Possibly, obesity promotes hypertension
partly through reduced direct vascular and renal NP responses as well
as impaired NP-mediated RAAS inhibition (Burnett et al., 1984; Shi
et al., 2001). NP deﬁciencymight contribute to the development of obe-
sity related hypertension directly through reduced vasodilatation
(Protter et al., 1996; van der Zander et al., 1999) and enhanced sodium
and water reabsorption (Sonnenberg et al., 1986; Harris et al., 1987;
Yoshimura et al., 1991), as well as decreased suppression of the renin–
angiotensin–aldosterone-system (RAAS). All of these mechanisms are
considered major contributing factors in obese, hypertensive patients
(Kurukulasuriya et al., 2011).
Moreover, enhanced sympathetic nervous system activity has been
implied in the development of obesity related arterial hypertension.
NP have been shown to attenuate muscle sympathetic nerve activity
(Floras, 1990, 1995), in part by blocking ganglionic neurotransmission
(Floras, 1995), thereby attenuating the reﬂex sympathetic response to
baroreceptor deactivation (Floras, 1990). Brunner-La Rocca et al.
demonstrated an inhibitory effect on systemic and cardiac sympathetic
nervous system activity for BNP at physiological levels (Brunner-La
Rocca et al., 2001). Thus, insufﬁcient NP-response might contribute to
enhanced sympathetic nervous system activity in the setting of obesity.
Ethnic differences have been reported in the prevalence of cardio-
metabolic disease, with a higher prevalence in subjects with African
(Taylor et al., 2010; Liu et al., 2013) or Hispanic ancestry (Guzman,
2012) compared to Caucasians. The reasons for these ethnic variances
remain elusive. Lifestyle and socioeconomic status are considered to
play a major role, however; interracial differences are preserved in
Africans and Caucasians with comparable socioeconomic status
(Sampson et al., 2014). One possible mechanism might be the
inadequately higher RAAS-activity in individuals of African origin
(Flack et al., 2010). Interestingly, signiﬁcant ethnic differences
were also found in NT-proBNP levels with the highest levels found in
non-Hispanic whites, followed by Hispanics, Chinese and African-
Americans in decreasing order (Choi et al., 2012). Due to theirmetabolic
effects and modulatory impact on RAAS activity (Burnett et al., 1984;
Johnson et al., 1988; Shi et al., 2001), it seems intriguing to speculate
that ethnic differences in developing hypertension and metabolic
disease might in part be mediated by variances in circulating NP levels
and the resulting change in modulation of the RAAS. However, the
issue is still poorly understood and further investigation is needed to
elucidate the meaning of interracial differences in the NP system.
Apart from their impact on blood pressure regulation, NPs also seem
to have a beneﬁcial effect cardiac remodeling in essential hypertension,
reducing left ventricular hypertrophy (LVH) (Rubattu et al., 2006). Con-
versely, conditions associated with NP deﬁciency result in an increased
risk for cardiac hypertrophy in hypertensive patients. Rubattu et al.
demonstrated that hypertensive patients with metabolic syndrome
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prevalence of LV hypertrophy compared to hypertensive subjects
without metabolic syndrome (Rubattu et al., 2007).
All in all, these ﬁndings suggest that lower NP levels are associated
with obesity and increased risk of metabolic and cardiovascular disease,
while higher NP levels come along with a more favorable cardiometa-
bolic phenotype.
5.4. Natriuretic peptides in heart failure and cardiac cachexia
Severe chronic heart failure (CHF) is associatedwithmetabolic alter-
ations and cardiac cachexia. A number of immunological and neurohor-
monal processes are involved in the genesis of heart failure-induced
cachexia, reviewed in (von Haehling et al., 2007; Martins et al., 2013).
The pathophysiology of cardiac cachexia is multifactorial, resulting
from several factors interacting in a complex system with metabolic,
immune and neurohormonal consequences, probably triggered to pro-
tect the heart from damage (Martins et al., 2013). Systemic NP levels
are elevated in CHF due to cardiac wall stress resulting from increased
end diastolic pressure. BNP and NT-proBNP have been well established
as diagnostic and prognostic markers for heart failure patients (Cowie
et al., 2003; Rothenburger et al., 2004; Januzzi et al., 2005; Fonarow
et al., 2007). With respect to their lipolytic properties and activation of
oxidative metabolism natriuretic peptides might contribute to weight
loss and cachexia in heart failure (McCord et al., 2004; McEntegart
et al., 2007; Polak et al., 2011) and evidence has been given in numerous
studies that high NP levels are associated with cardiac cachexia
(Horwich et al., 2001; Lavie et al., 2003; Melenovsky et al., 2013;
Stavrakis et al., 2013). However, through improvements in muscular
oxidative function, NP could also counteract the muscle ﬁber type
switch in heart failure patients. Patients with chronic heart failure
feature relative reductions in oxidative type 1 muscle ﬁbers, which
further limits aerobic exercise capacity.
These mechanisms are only plausible when NP mediated metabolic
responses do not desensitize due to chronic NP excess in heart failure.
We have addressed the questionwhether or not the ex vivo lipolytic re-
sponse to ANP is attenuated in isolated adipocytes from patients with
severely impaired left ventricular function in part through changes in
theNP receptor expression.We observed that the adipose tissue NP sys-
temdoes not desensitize in heart failure patients, as evidenced by a pre-
served lipolytic response to ANP (Birkenfeld et al., 2011a). The ﬁnding
has been conﬁrmed in different clinical settings (Polak et al., 2011;
Szabo et al., 2013). Whether metabolic responses to NP are also pre-
served in skeletal muscle is unknown.
6. Therapeutic potential of natriuretic
peptides in metabolic syndrome and its components
6.1. Cardiovascular disease
Recombinant NP analogs such as Carperitide (synthetic ANP) or
Nesiritide (synthetic BNP) have been approved for intravenous
treatment of acutely decompensated heart failure in Japan and the US.
However, the short plasma half life (Astrup et al., 1985), the need for
intravenous or subcutaneous infusion, and adverse events such as rele-
vant hypotension requiring drug discontinuation limit the clinical utility
(Suwa et al., 2005; Suzuki et al., 2013).
In the past, the recombinant BNP analog Nesiritide was widely used
for the treatment of acute decompensated heart failure in the US.
However, standard dose Nesiritide treatment increased mortality and
worsened renal function (Sackner-Bernstein et al., 2005a, 2005b).
Thus far, there is no evidence for a signiﬁcant beneﬁt of Nesiritide treat-
ment in heart failure fromplacebo-controlled clinical trials (Yancy et al.,
2008; O'Connor et al., 2011; Topol, 2011). Perhaps, Nesiritide may have
a neutral or even protective inﬂuence on renal functionwhen applied in
non-hypotensive doses (Chen et al., 2007;Mentzer et al., 2007;Witteleset al., 2007). In patients with congestive heart failure and reduced renal
function, the effect seems to be neutral (H.H. Chen et al., 2013).
More recently, Nesiritide has been tested in pulmonary hyperten-
sion patients. Nesiritide infusion reduced pulmonary artery and right
ventricular pressures in these patients (Michaels et al., 2005; T. Chen
et al., 2013).
Another option to augment the NP system is to block NP clearance.
In animal models inhibition of the NP degrading neutral endopeptidase
neprilysin increased NP plasma levels and promoted diuresis (Good
et al., 1995). In clinical trials, monotherapy with neutral endopeptidase
inhibitors showed poor results, so far. Acute and chronic effects on car-
diac output, vascular tone and blood pressure were minor (Northridge
et al., 1989; Bevan et al., 1992). Although neprilysin inhibitors in general
are well tolerated, long-term treatment with high doses of certain
neprilysin inhibitors, was associated with severe adverse events such
as severe aplastic anemia and angioedema (Cleland & Swedberg, 1998).
Combined neprilysin and RAAS inhibitionmay overcome the limited
efﬁcacy of neprilysin inhibitor monotherapy but is not without risks.
Recent in vivo data from animal models indicate that dual inhibition
of the RAAS and augmentation of the NP system might decelerate
tachycardia-induced left ventricular hypertrophy and chronic heart fail-
ure progression (Birner et al., 2012). Yet, the dual vasopeptidase inhib-
itor Omapatrilat that blocked ACE and neprilysin had to be withdrawn
from themarket owing to an excessive angioedema risk. More recently,
a large scale trial with 1328 mild to moderately hypertensive patients
conﬁrmed that dual inhibition of angiotensin II subtype 1 receptors
and neprilysin with LCZ696 decreases blood pressure more than angio-
tensin II subtype 1 receptor blockade alone (Ruilope et al., 2010).
LCZ696 is an unusual compound comprised of the angiotensin II sub-
type 1 receptor blocker Valsartan tied to a neprilysin inhibitor through
an ester bond. The combination is in late stage clinical development
for the treatment of heart failure and arterial hypertension.
Besides direct NP agonistic or augmenting strategies, other pharma-
cological strategies yield at downstreammediators of the NPRA depen-
dent pathway. Phosphodiesterase 5 (PDE5) inhibition selectively blocks
cyclic GMP degradation (Omori & Kotera, 2007), NPRA's and NPRB's
second messenger (Waldman et al., 1984; Song et al., 1988). So far,
phosphodiesterase inhibitors have been approved for the treatment of
pulmonary hypertension (Galiè et al., 2009) aswell as demand actuated
medication for the treatment of erectile dysfunction. In general, PDE5-
inhibitors are well tolerated when contraindications such as use of
nitrates in coronary heart disease are heeded (Bruzziches et al., 2013).
Sildenaﬁl is a highly selective PDE-5 inhibitor augmenting cGMP signal-
ing (Glossmann et al., 1999). Sildenaﬁl treatment may slow down
disease progression in early, asymptomatic diabetic cardiomyopathy
(Giannetta et al., 2012) and improve left ventricular function in heart
failure (Guazzi et al., 2011).
Novel strategies exploiting desirable cardiovascular effects of NPs for
the prevention and treatment of cardiovascular diseases are a matter of
ongoing preclinical and clinical research. Thus far, the ideal way to
clinically manipulate the NP system has not been found.
6.2. Metabolic disease
The notion that NP could be used as a therapeutic strategy in obesity,
the metabolic syndrome, or T2D has been recently entertained
(Costello-Boerrigter, 2013). Indeed, by improving lipidmobilization, ox-
idative metabolism, and blood pressure, NPs address a root cause of
these disorders. Regular physical training can restore circulating NP
concentrations and NP effectiveness in obese individuals (Moro et al.,
2005) in addition to the known beneﬁcial effects on improving weight
loss, insulin sensitivity, and cardiovascular risk (Goodpaster et al.,
2003; Houmard et al., 2004). Endurance training also improves skeletal
muscle oxidative capacity (Pruchnic et al., 2004). Recent experimental
data suggest that the positive effects of physical training are at least in
part caused by exercise-induced NP elevation in rodents and humans
22 N. Schlueter et al. / Pharmacology & Therapeutics 144 (2014) 12–27(Mitsuishi et al., 2008; Engeli et al., 2012). Asmentioned above, in amu-
rine model, increased BNP levels were protective against diet induced
obesity and insulin resistance (Miyashita et al., 2009) and large cross
sectional studies conﬁrm these data in human subjects (Sarzani et al.,
2004). Moreover, higher NP levels were also associated with a more fa-
vorable lipid proﬁle comprising lower circulating LDL and higher HDL
concentrations (Pervanidou et al., 2009;Wang et al., 2013). These ﬁnd-
ings suggest that NPs might be protective against dyslipidemia, which
conveys increased cardiovascular risk in obesity and T2D.
Dual ACE and neprilysin inhibition improved insulin sensitivity in
diabetic rats (Wang et al., 2003). The authors related the effect to
increased bradykinin levels and stimulation of the bradykinin receptor
B2. Regrettably, natriuretic peptide levels were not measured. Also,
other dual vasopeptidase inhibitorsmay improvemicrovascular circula-
tion including endoneurial blood ﬂow, which is important in the patho-
genesis of diabetic polyneuropathy (Davidson et al., 2007; Oltman et al.,
2009).
Downstream mediators of the NPRA pathway may also provide
treatment targets. Natriuretic peptides are considered to facilitate
their metabolic effects mainly via cGMP dependent GK-I activation.
(Sengenès et al., 2003; Mitsuishi et al., 2008; Miyashita et al., 2009).
Thus, activation of GK-I by othermeans is likely to have a similar impact
on energy homeostasis (Miyashita et al., 2009; Mitschke et al., 2013). A
well-known pharmacological target is phosphodiesterase-5 that de-
grades cyclic GMP. In murine models, long-term treatment with the
PDE-5 inhibitor Sildenaﬁl improves skeletal muscle metabolic index,
diet-induced insulin resistance and weight-gain (Ayala et al., 2007;
Rizzo et al., 2010; Handa et al., 2013). These ﬁndings are consistent
with the idea that augmented cGMP signaling rescues mitochondrial
function and promotes mitochondrial biogenesis.
Given their effects on mitochondrial metabolism, on lipid and
glucose metabolism, and on arterial blood pressure, NPs provide a par-
ticularly promising target for the treatment of obesity and its related
diseases. To date, many anti-obesity drugs were withdrawn from the
market due to their unfavorable cardiovascular proﬁle. In contrast, NP
system manipulation is a promising approach to simultaneously
address common cardiovascular and metabolic conditions.
7. Novel pharmacologic approaches
New strategies are needed to make the NP amenable for more
chronic treatments. CD-NP is a novel, chimeric NP analog that is ligand
to both natriuretic peptide receptors A and B and is more resistant to
proteolytic degradation compared to ANP and BNP. CD-NP is a fusion
product of CNP and the carboxyterminus of dendroaspis natriuretic
peptide (DNP) from the venom of the green mamba snake. Due to its
DNP-carboxyterminal tail CD-NP has a 13-, 4-, and threefold increased
half-life compared to ANP, BNP and CNP respectively (Dickey & Potter,
2011). CD-NP was designed to generate a peptide that combines “the
cardiac unloading, antiproliferative, antiﬁbrotic, and minimal hypoten-
sive properties of CNP with the renal-enhancing actions of DNP”
(McKie et al., 2010) and minimal adverse side effects. First data in
humans conﬁrms signiﬁcant natriuretic and diuretic effects as well as
RAAS suppressing properties with only slight changes in arterial blood
pressure (Lee et al., 2009). Recently, long-term subcutaneous treatment
with CD-NPwas found to signiﬁcantly attenuate left ventricular ﬁbrosis
in rats with unilateral nephrectomy-induced cardiac ﬁbrosis (Martin
et al., 2013). Current approaches yield at CD-NP-eluting patches that
can be applied locally for the treatment of localized myocardial ﬁbrosis,
as for example after myocardial infarction (Ng et al., 2013).
Another novel natriuretic peptide receptor-A (NPR-A) agonist PL-
3994 (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-
Cys)-Tyr-[Argmimetic]-NH(2)), has been designed and proven high af-
ﬁnity to NPRA. PL-3994 induces a sustained cGMP generation in NPRAs.
Interestingly, PL-3994 has been reported to be resistant to degradation
by human neutral endopeptidase. Thus, PL-3994 might have a proﬁlepredictive of longer clinical activity than other related peptides
(Edelson et al., 2013).
Pegylation, the covalent binding of poly(ethylene glycol) (PEG) to
peptides and proteins, is another approach to prolong substance release
and to delay degradation (Roberts et al., 2002; Veronese & Pasut, 2005;
Werle & Bernkop-Schnürch, 2006). Nesher et al. reversibly pegylated
ANP and thereby achieved prolonged elevation of ANP plasma levels
and blood pressure reduction in hypertensive rats (Nesher et al.,
2007).More recently; ANPhas been fused to the Fc-domain of immuno-
globulin G (IgG) reaching plasma half-times approximately 2 orders of
magnitude longer than unfused ANP (Mezo et al., 2012). However, Fc-
ANP was signiﬁcantly weaker than the unconjugated peptide.
Recently, the Wang lab described miRNA-425 (miR-425) as a novel
negative regulator of ANP expression. miR-425 is expressed in human
atria and ventricles and silenced NPPA mRNA in an allele-speciﬁc man-
ner (Arora et al., 2013). Possibly,miR-425 antagonists could bedesigned
to increase ANP levels in order to treat disorders of salt overload, includ-
ing hypertension and heart failure and metabolic disease.
8. Conclusion
Natriuretic peptides are well known for their renal and cardiovascu-
lar effects. They are widely used as prognostic biomarkers in heart
failure and a number of therapeutic strategies aim to exploit the hypo-
tensive, natriuretic and antihypertrophic properties of the NP system.
Metabolic and cardiovascular diseases are closely linked and constitute
a major public health issue in industrialized countries. A growing body
of evidence indicates that NPs might be a crucial piece of the puzzle
linking the heart to energy metabolism. In paradigm, the heart can be
regarded a sensor chaperoning whole body lipid and glucose metabo-
lism. Connecting cardiovascular and energy metabolism, the NP system
provides a bouquet of options for pharmacological intervention. To date,
recombinant peptides and inhibitors of the degradation process of NP
are the most promising molecules in this regard. Moreover, mi-RNA
425 has recently been shown to be a regulator of ANP and as such,
might be a suitable target to increase ANP concentrations. Time will
show, if it will be possible to treat cardiometabolic diseases with NPmi-
metic molecules.
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